Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

Mpox: The alarm went off. Have we gone back to sleep?

Olliaro P. et al, (2024), PLOS Neglected Tropical Diseases, 18, e0011871 - e0011871

Experiences and challenges with the new European Clinical Trials Regulation.

Patrick-Brown TDJH. et al, (2024), Trials, 25

Bubonic plague: can the size of buboes be accurately and consistently measured with a digital calliper?

Bourner J. et al, (2023), Trials, 24

Variability in clinical assessment of clade IIb mpox lesions

Jones B. et al, (2023), International Journal of Infectious Diseases, 137, 60 - 62

A systematic review of the clinical profile of patients with bubonic plague and the outcome measures used in research settings.

Bourner J. et al, (2023), PLoS neglected tropical diseases, 17

Laboratory Diagnosis of Mpox, Central African Republic, 2016-2022.

Garba-Ouangole S. et al, (2023), Emerging infectious diseases, 29, 1846 - 1849

[MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks].

Kali S. et al, (2023), Virologie (Montrouge, France), 27, 23 - 26

MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks.

Kali S. et al, (2023), Virologie (Montrouge, France), 27, 12 - 15

MOSAIC: A cohort study of human mpox virus disease.

Pesonel E. et al, (2023), Wellcome open research, 8

Tecovirimat for Monkeypox in Central African Republic under Expanded Access.

Mbrenga F. et al, (2022), The New England journal of medicine, 387, 2294 - 2295

A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever

Olayinka AT. et al, (2022), PLOS Neglected Tropical Diseases, 16, e0010089 - e0010089

The impact of COVID-19 on clinical research for Neglected Tropical Diseases (NTDs): A case study of bubonic plague.

Rasoanaivo TF. et al, (2021), PLoS neglected tropical diseases, 15

Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.

Merson L. et al, (2021), PLoS neglected tropical diseases, 15

An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial.

Randremanana RV. et al, (2020), Trials, 21

Real world interpretation of GEC-ESTRO image-guided brachytherapy recommendations for cervix cancer

Diez P. et al, (2020), RADIOTHERAPY AND ONCOLOGY, 152, S1091 - S1092